SBI Securities Co. Ltd. Invests $46,000 in Kenvue Inc. (NYSE:KVUE)

SBI Securities Co. Ltd. purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,150 shares of the company’s stock, valued at approximately $46,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue during the fourth quarter worth about $29,000. SRS Capital Advisors Inc. boosted its holdings in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after buying an additional 571 shares in the last quarter. Fortitude Family Office LLC boosted its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in Kenvue during the third quarter worth about $35,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 2.0 %

Kenvue stock opened at $23.90 on Tuesday. The firm has a market cap of $45.67 billion, a price-to-earnings ratio of 45.09, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a fifty day moving average price of $21.69 and a two-hundred day moving average price of $22.35.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analysts Set New Price Targets

A number of research firms recently commented on KVUE. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Citigroup reduced their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.